MIT Technology Review reported that a stealth-mode biotech is pitching decorticated human-like clones — "bodyoids" — as a transplant-organ source and a longevity tool. The biology is wildly underdeveloped, the ethics are off, and the broader cost is to public trust in mainstream geroscience.
On March 30, 2026, MIT Technology Review published an investigation into R3 Biotechnologies, a stealth-mode startup pitching what it calls "bodyoids" — decorticated human-like clones grown without a neocortex, intended as a source of transplant organs and tissues. The reporting describes the company's funding network (Silicon Valley investors, alleged courting of the federal research agency ARPA-H), its founder's longevity-research lineage (an Aubrey de Grey "protégé"), and the broader Vitalist subculture that surrounds it.
We covered the story carefully because it sits squarely inside the longevity industry — and because we think the longevity-research community needs to be loud about why this isn't the future we should accept.
The argument goes: organ transplant waiting lists are long and tragic, animal-model research has limits, and aging-related organ failure is one of the major causes of late-life suffering. If we could grow human-like bodies that never develop sentience — no cortex, no consciousness — we could harvest tissue-matched organs on demand and run aging research without the limits of mouse and primate models. The reporting describes a "Longevity Biotech Fellowship" roadmap estimating that a proof-of-concept brainless clone would cost about $40M to produce. Speakers at private longevity events have presented this as a "final bid to defeat aging."
Three reasons, in increasing order of importance.
Scientific. The biology required to grow a tissue-matched, organ-functional human body without a sentient brain is not in hand. Neural and non-neural tissue codevelop and signal across each other through embryogenesis; isolating one from the other is not a small engineering challenge but a fundamental open biology problem. The roadmap's "$40M proof of concept" estimate is wildly optimistic by any honest reading of the developmental-biology literature.
Ethical. Even if "no neocortex" were a clean enough boundary to guarantee absence of experience — and it isn't; the literature on the role of the thalamus, brainstem, and subcortical structures in basic awareness is unsettled at best — the framework treats human-derived biology as a resource to be manufactured. Researchers we trust in the bioethics community have flagged this as the kind of project that should not be pursued at any funding level, including private. One researcher interviewed in the reporting flatly said: "How do you demonstrate safety? What is safety when you're trying to create an abnormal human?"
Strategic. The most damaging effect of stories like this is what they do to public trust in mainstream geroscience. The legitimate longevity field — biomarkers of aging, geroprotector trials, NLRP3 inhibitors, GLP-1s, exercise prescription, sleep biology — is in the middle of a real-evidence inflection. Public association of that work with "brainless clones in stealth-mode biotech" sets back funding, regulatory cooperation, and reader trust in everything we cover.
IQ Healthspan covers the longevity-science field because we believe extended healthspan, supported by evidence, is a worthwhile project. We do not believe every project that markets itself as "longevity" is part of that mission. The bodyoid concept, as described in the reporting, is a high-cost, high-ethical-risk detour from the work the field should be doing — and we think it deserves clear pushback from people inside the longevity community, not silence.
Most of what R3 is publicly doing is animal-model replacement work, which is uncontroversial. The bodyoid concept is the headline ambition, presented at private events. The interesting question isn't whether R3 will succeed at its stated goal — we don't think it will — but whether the longevity community's funders, conferences, and reporters will keep platforming this framing. Reader pressure on that matters more than the underlying biology, which is many years from any meaningful demonstration.
For an honest assessment of what's actually working in the field, see our pharmacology overview and state-of-the-field summary. Those are where the real work is — not in stealth pitches about manufactured bodies.